SEC Form 4
Nektar Therapeutics (NKTR) insider trading
In the 12 months to Oct 26, 2026, 3 NKTR insiders reported open-market sales of $2.4M across 13 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $2.4M
- 13 filings · 3 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 4 of 13
- $2.1M of $2.4M sold (86%)
Who traded NKTR, and when
- Sale
- Sale, pre-arranged (10b5-1)
NKTR daily close from Oct 27, 2025 to Oct 26, 2026, between $35.12 and $100.35, last $37.29. 13 sale and 0 purchase filings by 3 insiders, marked at their filing dates. Howard W. Robin, President & CEO: sold $1.4M across 5 filings, first filed Nov 25, 2025, last Aug 20, 2026. Jonathan Zalevsky, Chief R&D Officer: sold $974.2K across 7 filings, first filed Nov 25, 2025, last Aug 20, 2026. Mark Andrew Wilson, Chief Legal Officer: sold $34.2K across 1 filing, first filed Nov 25, 2025, last Nov 25, 2025.
Largest mark · tap a row for others
Howard W. Robin · President & CEO
Sale $1,215,056
20,000 shares at $60.75 avg
Filed Jun 18, 2026 · traded Jun 16
Pre-arranged (10b5-1) · close on filing date $60.98
Howard W. Robin · President & CEO
President & CEO
$1.4M soldJonathan Zalevsky · Chief R&D Officer
Chief R&D Officer
$974.2K soldMark Andrew Wilson · Chief Legal Officer
Chief Legal Officer
$34.2K soldOpen-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Howard W. Robin | President & CEO | $1.4M | — | 5 | 85% of sales | |
| Jonathan Zalevsky | Chief R&D Officer | $974.2K | — | 7 | 89% of sales | |
| Mark Andrew Wilson | Chief Legal Officer | $34.2K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Howard W. Robin President & CEO | Sale | 418 | $71.98 | $30.1K | 54,627 | |
traded | Jonathan Zalevsky Chief R&D Officer | Sale | 186 | $71.98 | $13.4K | 9,570 | |
traded | Jonathan Zalevsky Chief R&D Officer | SalePre-arranged (10b5-1) | 5,681 | $70.00 | $397.7K | 9,756 | |
traded | Howard W. Robin President & CEO | SalePre-arranged (10b5-1) | 20,000 | $60.75 | $1.2M | 59,545 | |
traded | Jonathan Zalevsky Chief R&D Officer | SalePre-arranged (10b5-1) | 5,538 | $60.71 | $336.2K | 15,437 | |
traded | Howard W. Robin President & CEO | Sale | 444 | $65.51 | $29.1K | 75,045 | |
traded | Jonathan Zalevsky Chief R&D Officer | Sale | 199 | $65.51 | $13.0K | 20,975 | |
traded | Howard W. Robin President & CEO | Sale | 423 | $73.00 | $30.9K | 75,489 | |
traded | Jonathan Zalevsky Chief R&D Officer | Sale | 180 | $73.00 | $13.1K | 21,174 | |
traded | Jonathan Zalevsky Chief R&D Officer | SalePre-arranged (10b5-1) | 3,867 | $35.67 | $137.9K | 21,354 | |
traded | Howard W. Robin President & CEO | Sale | 2,207 | $54.28 | $119.8K | 54,245 | |
traded | Mark Andrew Wilson Chief Legal Officer | Sale | 630 | $54.28 | $34.2K | 21,585 | |
traded | Jonathan Zalevsky Chief R&D Officer | Sale | 1,157 | $54.28 | $62.8K | 18,971 |
GET /stocks/filings/vX/form-4?tickers=NKTR&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"NKTR"
],
"issuer_cik": "0000906709",
"owner_cik": "0001206869",
"accession_number": "0001193125-26-359586",
"form_type": "4",
"filing_date": "2026-08-20",
"period_of_report": "2026-08-18",
"issuer_name": "NEKTAR THERAPEUTICS",
"issuer_trading_symbol": "NKTR",
"owner_name": "ROBIN HOWARD W",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President & CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-18",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 418,
"transaction_price_per_share": 71.98,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 54627,
"transaction_value": 30087.640000000003,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person."
},
{
"id": "F2",
"description": "This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer."
}
]
},
{
"tickers": [
"NKTR"
],
"issuer_cik": "0000906709",
"owner_cik": "0001789857",
"accession_number": "0001193125-26-359588",
"form_type": "4",
"filing_date": "2026-08-20",
"period_of_report": "2026-08-18",
"issuer_name": "NEKTAR THERAPEUTICS",
"issuer_trading_symbol": "NKTR",
"owner_name": "Zalevsky Jonathan",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief R&D Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-18",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 186,
"transaction_price_per_share": 71.98,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 9570,
"transaction_value": 13388.28,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person."
},
{
"id": "F2",
"description": "This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 10 records
- Grants and awards10 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Nektar Therapeutics' CEO sold stock?
Yes. Howard W. Robin (CEO) sold 23,492 shares ($1.4M) between Nov 2025 and Aug 2026, $1.2M of it under a pre-arranged 10b5-1 plan.
How current is NKTR’s insider data?
These are NKTR Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track NKTR insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for NKTR every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.